NHS Hospitals: Apheresis

Baroness Ritchie of Downpatrick Excerpts
Wednesday 9th October 2024

(2 months, 1 week ago)

Lords Chamber
Read Full debate Read Hansard Text Watch Debate Read Debate Ministerial Extracts
Asked by
Baroness Ritchie of Downpatrick Portrait Baroness Ritchie of Downpatrick
- Hansard - -

To ask His Majesty’s Government what steps they are taking to support increasing apheresis capacity in NHS hospitals in England.

Baroness Merron Portrait The Parliamentary Under-Secretary of State, Department of Health and Social Care (Baroness Merron) (Lab)
- View Speech - Hansard - - - Excerpts

The Government are aware of the issues around apheresis capacity within the National Health Service impacting patient services, including stem cell donations. A departmentally led working group met for the first time last month to examine existing apheresis capacity and to develop solutions, and it will report in the spring. This working group includes members of the UK stem cell register, health professionals and service providers, and it aims to develop an evidence base by which strategic decisions around capacity can be established.

Baroness Ritchie of Downpatrick Portrait Baroness Ritchie of Downpatrick (Lab)
- View Speech - Hansard - -

My Lords, I thank my noble friend Lady Merron for her very helpful reply. Only last month I chaired a round table in your Lordships’ House on apheresis capacity. Therefore, given the rapid developments in cell and gene therapies and related international regulation over the last few years, what plans do the Government have to update legislation governing the use of substance of human origin and the development of advanced therapeutical medicinal products to better utilise modern technologies such as apheresis platforms?

Baroness Merron Portrait Baroness Merron (Lab)
- View Speech - Hansard - - - Excerpts

I am grateful to my noble friend for her work in this regard. I certainly share the view that there have been very rapid developments in cell and gene therapies over the past few years, and there is tremendous potential for these therapies to address the root cause of diseases and to offer life-changing outcomes for patients. So, we are working with devolved Governments and with key stakeholders to review the EU standards and requirements, and to consider our approach in light of the changes introduced by the EU SoHO regulations, which will take account of innovation within the sector.